FindMyKOL
Clinical trialNCT07679282RecruitingPhase 4Interventional

A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults

NCT07679282 is a phase 4 interventional trial sponsored by Sairam Parthasarathy. As of 21 Nov 2026, it is recruiting participants. It studies Atomoxetine-oxybutynin in Obstructive Sleep Apnea (OSA). The registry lists an enrollment of 2,400 participants at 4 sites in 1 country. The registry lists a start date of 4 Sept 2026 and a primary completion date of 1 Mar 2030.

SponsorSairam ParthasarathyEnrollment2,400Obstructive Sleep Apnea (OSA)
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07679282
FieldValue
Registry IDNCT07679282
StatusRecruiting
PhasePhase 4
Study typeInterventional trial
Lead sponsorSairam Parthasarathy
Enrollment2,400
Registered sites4
Countries1
ConditionsObstructive Sleep Apnea (OSA)
DrugsAtomoxetine-oxybutynin
Start4 Sept 2026
Primary completion1 Mar 2030
Study completion1 May 2032
Last update posted19 Oct 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible participants will be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions. Over the course of one year, participants will attend two in-person visits and take part in four phone check-ins to complete surveys, report any side effects, and discuss how well they are following their assigned treatment.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arizona, United States1 site, 1 recruiting
  • Banner University Medical Center Tucson

    Tucson

    Monisha Das Ireland, MDSaif Mashaqi, MDSairam Parthasarathy, MD
    Recruiting
California, United States1 site, 1 recruiting
  • Stanford Medical Center

    Redwood City

    Clete Kushida, MD, PhD
    Recruiting
Florida, United States1 site
  • University of Miami Miller School of Medicine

    Miami

    Alexandre Abreu, MDGirardin Jean-Louis, PhD
    Not, yet, recruiting
Maryland, United States1 site, 1 recruiting
  • University of Maryland Baltimore

    Baltimore

    Emerson Wickwire, PhD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 site, 1 recruitingCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 site, 1 recruitingMD1DelawareDEArizona: 1 site, 1 recruitingAZ1UtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atomoxetine-oxybutynin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07679282

Each answer restates registry values shown on this page.

What is NCT07679282?

NCT07679282 is a phase 4 interventional trial sponsored by Sairam Parthasarathy. It studies Atomoxetine-oxybutynin in Obstructive Sleep Apnea (OSA).

Is NCT07679282 recruiting?

As of 21 Nov 2026, it is recruiting participants. 3 of its 4 sites list their own status as recruiting.

Who leads NCT07679282?

The registry names Sairam Parthasarathy, MD (principal investigator, University of Arizona) as the overall official.

Where does NCT07679282 run?

The registry lists 4 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT07679282 study?

The registered drug and biological interventions are Atomoxetine-oxybutynin.

When is NCT07679282 expected to complete?

The registry lists a primary completion date of 1 Mar 2030 and a study completion date of 1 May 2032. The sponsor last updated the record on 19 Oct 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.